Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course
Identifieur interne : 002741 ( Istex/Corpus ); précédent : 002740; suivant : 002742Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course
Auteurs : Ann M. Reed ; Erik Peterson ; Hatice Bilgic ; Steven R. Ytterberg ; Shreyasee Amin ; Molly S. Hein ; Cynthia S. Crowson ; Floranne Ernste ; Emily Baechler GillespieSource :
- Arthritis & Rheumatism [ 0004-3591 ] ; 2012-12.
Abstract
Objective: Muscle enzyme levels are insensitive markers of disease activity in juvenile and adult dermatomyositis (DM), especially during the active treatment phase. To improve our ability to monitor DM disease activity longitudinally, especially in the presence of immunomodulating agents, we prospectively evaluated whether interferon (IFN)–dependent peripheral blood gene and chemokine signatures could serve as sensitive and responsive biomarkers for change in disease activity in adult and juvenile DM. Methods: Peripheral blood and clinical data were collected from 51 patients with juvenile or adult DM prospectively over 2 study visits. We performed disease activity measurements and calculated whole‐blood type I IFN gene and chemokine scores. We also measured serum levels of other proinflammatory cytokines, including interleukin‐6 (IL‐6). Results: Changes in juvenile and adult DM global disease activity correlated positively and significantly with changes in the type I IFN gene score before adjustment for medication use (r = 0.33, P = 0.023) and with changes in the IFN chemokine score before and after adjustment for medication use (r = 0.53, P < 0.001 and r = 0.50, P < 0.001, respectively). Changes in muscle and extramuscular visual analog scale (VAS) scores correlated positively with changes in IFN gene and chemokine scores (P = 0.002, P < 0.001, P = 0.095, P < 0.001). Serum levels of IL‐6, IL‐8, and tumor necrosis factor α (TNFα) correlated positively with changes in global, muscle, and extramuscular VAS scores (P < 0.05). Conclusion: Our findings suggest that changes in type I IFN gene and chemokine scores as well as in levels of IL‐6, IL‐8, and TNFα may serve as sensitive and responsive longitudinal biomarkers of change in disease activity in juvenile and adult DM, even in the presence of immunomodulating agents.
Url:
DOI: 10.1002/art.34659
Links to Exploration step
ISTEX:AB92DF4B4E124024B3FC801A66D93257186F75A1Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course</title><author><name sortKey="Reed, Ann M" sort="Reed, Ann M" uniqKey="Reed A" first="Ann M." last="Reed">Ann M. Reed</name><affiliation><mods:affiliation>Mayo Clinic, Rochester, Minnesota</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: reed.ann18@mayo.edu</mods:affiliation></affiliation><affiliation><mods:affiliation>Correspondence address: Mayo Clinic, Division of Rheumatology, E15, 200 First Street SW, Rochester, MN 55905</mods:affiliation></affiliation></author><author><name sortKey="Peterson, Erik" sort="Peterson, Erik" uniqKey="Peterson E" first="Erik" last="Peterson">Erik Peterson</name><affiliation><mods:affiliation>University of Minnesota, Minneapolis</mods:affiliation></affiliation></author><author><name sortKey="Bilgic, Hatice" sort="Bilgic, Hatice" uniqKey="Bilgic H" first="Hatice" last="Bilgic">Hatice Bilgic</name><affiliation><mods:affiliation>University of Minnesota, Minneapolis</mods:affiliation></affiliation></author><author><name sortKey="Ytterberg, Steven R" sort="Ytterberg, Steven R" uniqKey="Ytterberg S" first="Steven R." last="Ytterberg">Steven R. Ytterberg</name><affiliation><mods:affiliation>Mayo Clinic, Rochester, Minnesota</mods:affiliation></affiliation></author><author><name sortKey="Amin, Shreyasee" sort="Amin, Shreyasee" uniqKey="Amin S" first="Shreyasee" last="Amin">Shreyasee Amin</name><affiliation><mods:affiliation>Mayo Clinic, Rochester, Minnesota</mods:affiliation></affiliation></author><author><name sortKey="Hein, Molly S" sort="Hein, Molly S" uniqKey="Hein M" first="Molly S." last="Hein">Molly S. Hein</name><affiliation><mods:affiliation>Mayo Clinic, Rochester, Minnesota</mods:affiliation></affiliation></author><author><name sortKey="Crowson, Cynthia S" sort="Crowson, Cynthia S" uniqKey="Crowson C" first="Cynthia S." last="Crowson">Cynthia S. Crowson</name><affiliation><mods:affiliation>Mayo Clinic, Rochester, Minnesota</mods:affiliation></affiliation></author><author><name sortKey="Ernste, Floranne" sort="Ernste, Floranne" uniqKey="Ernste F" first="Floranne" last="Ernste">Floranne Ernste</name><affiliation><mods:affiliation>Mayo Clinic, Rochester, Minnesota</mods:affiliation></affiliation></author><author><name sortKey="Gillespie, Emily Baechler" sort="Gillespie, Emily Baechler" uniqKey="Gillespie E" first="Emily Baechler" last="Gillespie">Emily Baechler Gillespie</name><affiliation><mods:affiliation>University of Minnesota, Minneapolis</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:AB92DF4B4E124024B3FC801A66D93257186F75A1</idno><date when="2012" year="2012">2012</date><idno type="doi">10.1002/art.34659</idno><idno type="url">https://api.istex.fr/ark:/67375/WNG-XQC5PHV8-N/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">002741</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">002741</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main">Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course</title><author><name sortKey="Reed, Ann M" sort="Reed, Ann M" uniqKey="Reed A" first="Ann M." last="Reed">Ann M. Reed</name><affiliation><mods:affiliation>Mayo Clinic, Rochester, Minnesota</mods:affiliation></affiliation><affiliation><mods:affiliation>E-mail: reed.ann18@mayo.edu</mods:affiliation></affiliation><affiliation><mods:affiliation>Correspondence address: Mayo Clinic, Division of Rheumatology, E15, 200 First Street SW, Rochester, MN 55905</mods:affiliation></affiliation></author><author><name sortKey="Peterson, Erik" sort="Peterson, Erik" uniqKey="Peterson E" first="Erik" last="Peterson">Erik Peterson</name><affiliation><mods:affiliation>University of Minnesota, Minneapolis</mods:affiliation></affiliation></author><author><name sortKey="Bilgic, Hatice" sort="Bilgic, Hatice" uniqKey="Bilgic H" first="Hatice" last="Bilgic">Hatice Bilgic</name><affiliation><mods:affiliation>University of Minnesota, Minneapolis</mods:affiliation></affiliation></author><author><name sortKey="Ytterberg, Steven R" sort="Ytterberg, Steven R" uniqKey="Ytterberg S" first="Steven R." last="Ytterberg">Steven R. Ytterberg</name><affiliation><mods:affiliation>Mayo Clinic, Rochester, Minnesota</mods:affiliation></affiliation></author><author><name sortKey="Amin, Shreyasee" sort="Amin, Shreyasee" uniqKey="Amin S" first="Shreyasee" last="Amin">Shreyasee Amin</name><affiliation><mods:affiliation>Mayo Clinic, Rochester, Minnesota</mods:affiliation></affiliation></author><author><name sortKey="Hein, Molly S" sort="Hein, Molly S" uniqKey="Hein M" first="Molly S." last="Hein">Molly S. Hein</name><affiliation><mods:affiliation>Mayo Clinic, Rochester, Minnesota</mods:affiliation></affiliation></author><author><name sortKey="Crowson, Cynthia S" sort="Crowson, Cynthia S" uniqKey="Crowson C" first="Cynthia S." last="Crowson">Cynthia S. Crowson</name><affiliation><mods:affiliation>Mayo Clinic, Rochester, Minnesota</mods:affiliation></affiliation></author><author><name sortKey="Ernste, Floranne" sort="Ernste, Floranne" uniqKey="Ernste F" first="Floranne" last="Ernste">Floranne Ernste</name><affiliation><mods:affiliation>Mayo Clinic, Rochester, Minnesota</mods:affiliation></affiliation></author><author><name sortKey="Gillespie, Emily Baechler" sort="Gillespie, Emily Baechler" uniqKey="Gillespie E" first="Emily Baechler" last="Gillespie">Emily Baechler Gillespie</name><affiliation><mods:affiliation>University of Minnesota, Minneapolis</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j" type="main">Arthritis & Rheumatism</title><title level="j" type="alt">ARTHRITIS AND RHEUMATISM</title><idno type="ISSN">0004-3591</idno><idno type="eISSN">1529-0131</idno><imprint><biblScope unit="vol">64</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="4078">4078</biblScope><biblScope unit="page" to="4086">4086</biblScope><biblScope unit="page-count">9</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2012-12">2012-12</date></imprint><idno type="ISSN">0004-3591</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0004-3591</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objective: Muscle enzyme levels are insensitive markers of disease activity in juvenile and adult dermatomyositis (DM), especially during the active treatment phase. To improve our ability to monitor DM disease activity longitudinally, especially in the presence of immunomodulating agents, we prospectively evaluated whether interferon (IFN)–dependent peripheral blood gene and chemokine signatures could serve as sensitive and responsive biomarkers for change in disease activity in adult and juvenile DM. Methods: Peripheral blood and clinical data were collected from 51 patients with juvenile or adult DM prospectively over 2 study visits. We performed disease activity measurements and calculated whole‐blood type I IFN gene and chemokine scores. We also measured serum levels of other proinflammatory cytokines, including interleukin‐6 (IL‐6). Results: Changes in juvenile and adult DM global disease activity correlated positively and significantly with changes in the type I IFN gene score before adjustment for medication use (r = 0.33, P = 0.023) and with changes in the IFN chemokine score before and after adjustment for medication use (r = 0.53, P < 0.001 and r = 0.50, P < 0.001, respectively). Changes in muscle and extramuscular visual analog scale (VAS) scores correlated positively with changes in IFN gene and chemokine scores (P = 0.002, P < 0.001, P = 0.095, P < 0.001). Serum levels of IL‐6, IL‐8, and tumor necrosis factor α (TNFα) correlated positively with changes in global, muscle, and extramuscular VAS scores (P < 0.05). Conclusion: Our findings suggest that changes in type I IFN gene and chemokine scores as well as in levels of IL‐6, IL‐8, and TNFα may serve as sensitive and responsive longitudinal biomarkers of change in disease activity in juvenile and adult DM, even in the presence of immunomodulating agents.</div></front></TEI><istex><corpusName>wiley</corpusName><keywords><teeft><json:string>disease activity</json:string><json:string>chemokine</json:string><json:string>chemokine score</json:string><json:string>cytokine</json:string><json:string>gene score</json:string><json:string>dermatomyositis</json:string><json:string>biomarkers</json:string><json:string>myositis</json:string><json:string>chemokines</json:string><json:string>extramuscular</json:string><json:string>serum level</json:string><json:string>myopathy</json:string><json:string>disease activity measure</json:string><json:string>idiopathic</json:string><json:string>medication</json:string><json:string>cmas</json:string><json:string>interferon</json:string><json:string>peripheral blood</json:string><json:string>inflammatory</json:string><json:string>median</json:string><json:string>arthritis rheum</json:string><json:string>cytokine value</json:string><json:string>datum</json:string><json:string>global assessment</json:string><json:string>juvenile idiopathic inflammatory myopathy</json:string><json:string>rheum</json:string><json:string>muscle score</json:string><json:string>study visit</json:string><json:string>juvenile dermatomyositis</json:string><json:string>cytokine level</json:string><json:string>mayo clinic</json:string><json:string>immunomodulating agent</json:string><json:string>extramuscular score</json:string><json:string>global disease activity</json:string><json:string>monocyte chemotactic protein</json:string><json:string>tumor necrosis factor</json:string><json:string>adult dermatomyositis</json:string><json:string>sensitive measure</json:string><json:string>visual analog scale</json:string><json:string>muscle tissue</json:string><json:string>biomarker level</json:string><json:string>expression level</json:string><json:string>muscle enzyme</json:string><json:string>idiopathic inflammatory myopathy</json:string><json:string>muscle enzyme level</json:string><json:string>plasmacytoid dendritic cell</json:string><json:string>gene</json:string><json:string>global</json:string><json:string>correlated</json:string></teeft></keywords><author><json:item><name>Ann M. Reed</name><affiliations><json:string>Mayo Clinic, Rochester, Minnesota</json:string><json:string>E-mail: reed.ann18@mayo.edu</json:string><json:string>Correspondence address: Mayo Clinic, Division of Rheumatology, E15, 200 First Street SW, Rochester, MN 55905</json:string></affiliations></json:item><json:item><name>Erik Peterson</name><affiliations><json:string>University of Minnesota, Minneapolis</json:string></affiliations></json:item><json:item><name>Hatice Bilgic</name><affiliations><json:string>University of Minnesota, Minneapolis</json:string></affiliations></json:item><json:item><name>Steven R. Ytterberg</name><affiliations><json:string>Mayo Clinic, Rochester, Minnesota</json:string></affiliations></json:item><json:item><name>Shreyasee Amin</name><affiliations><json:string>Mayo Clinic, Rochester, Minnesota</json:string></affiliations></json:item><json:item><name>Molly S. Hein</name><affiliations><json:string>Mayo Clinic, Rochester, Minnesota</json:string></affiliations></json:item><json:item><name>Cynthia S. Crowson</name><affiliations><json:string>Mayo Clinic, Rochester, Minnesota</json:string></affiliations></json:item><json:item><name>Floranne Ernste</name><affiliations><json:string>Mayo Clinic, Rochester, Minnesota</json:string></affiliations></json:item><json:item><name>Emily Baechler Gillespie</name><affiliations><json:string>University of Minnesota, Minneapolis</json:string></affiliations></json:item></author><articleId><json:string>ART34659</json:string></articleId><arkIstex>ark:/67375/WNG-XQC5PHV8-N</arkIstex><language><json:string>eng</json:string></language><originalGenre><json:string>article</json:string></originalGenre><abstract>Objective: Muscle enzyme levels are insensitive markers of disease activity in juvenile and adult dermatomyositis (DM), especially during the active treatment phase. To improve our ability to monitor DM disease activity longitudinally, especially in the presence of immunomodulating agents, we prospectively evaluated whether interferon (IFN)–dependent peripheral blood gene and chemokine signatures could serve as sensitive and responsive biomarkers for change in disease activity in adult and juvenile DM. Methods: Peripheral blood and clinical data were collected from 51 patients with juvenile or adult DM prospectively over 2 study visits. We performed disease activity measurements and calculated whole‐blood type I IFN gene and chemokine scores. We also measured serum levels of other proinflammatory cytokines, including interleukin‐6 (IL‐6). Results: Changes in juvenile and adult DM global disease activity correlated positively and significantly with changes in the type I IFN gene score before adjustment for medication use (r = 0.33, P = 0.023) and with changes in the IFN chemokine score before and after adjustment for medication use (r = 0.53, P > 0.001 and r = 0.50, P > 0.001, respectively). Changes in muscle and extramuscular visual analog scale (VAS) scores correlated positively with changes in IFN gene and chemokine scores (P = 0.002, P > 0.001, P = 0.095, P > 0.001). Serum levels of IL‐6, IL‐8, and tumor necrosis factor α (TNFα) correlated positively with changes in global, muscle, and extramuscular VAS scores (P > 0.05). Conclusion: Our findings suggest that changes in type I IFN gene and chemokine scores as well as in levels of IL‐6, IL‐8, and TNFα may serve as sensitive and responsive longitudinal biomarkers of change in disease activity in juvenile and adult DM, even in the presence of immunomodulating agents.</abstract><qualityIndicators><score>10</score><pdfWordCount>5623</pdfWordCount><pdfCharCount>36175</pdfCharCount><pdfVersion>1.3</pdfVersion><pdfPageCount>9</pdfPageCount><pdfPageSize>612 x 792 pts (letter)</pdfPageSize><pdfWordsPerPage>625</pdfWordsPerPage><pdfText>true</pdfText><refBibsNative>true</refBibsNative><abstractWordCount>285</abstractWordCount><abstractCharCount>1848</abstractCharCount><keywordCount>0</keywordCount></qualityIndicators><title>Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course</title><pmid><json:string>22886447</json:string></pmid><genre><json:string>article</json:string></genre><host><title>Arthritis & Rheumatism</title><language><json:string>unknown</json:string></language><doi><json:string>10.1002/(ISSN)1529-0131</json:string></doi><issn><json:string>0004-3591</json:string></issn><eissn><json:string>1529-0131</json:string></eissn><publisherId><json:string>ART</json:string></publisherId><volume>64</volume><issue>12</issue><pages><first>4078</first><last>4086</last><total>9</total></pages><genre><json:string>journal</json:string></genre><subject><json:item><value>Myositis</value></json:item><json:item><value>Myositis</value></json:item></subject></host><namedEntities><unitex><date><json:string>2012</json:string></date><geogName></geogName><orgName><json:string>International Myositis Assessment and Clinical Studies Group</json:string><json:string>Juvenile Dermatomyositis Disease Activity Collaborative Study Group</json:string><json:string>International Myositis and Clinical Studies Group (IMACS)</json:string><json:string>University of Minnesota</json:string><json:string>Division of Rheumatology</json:string><json:string>Arthritis Foundation</json:string></orgName><orgName_funder></orgName_funder><orgName_provider></orgName_provider><persName><json:string>Emily Baechler</json:string><json:string>Ann M. Reed</json:string><json:string>Baechler Gillespie</json:string><json:string>Peterson</json:string><json:string>Hatice Bilgic</json:string><json:string>AL Use</json:string><json:string>Steven R. Ytterberg</json:string><json:string>Molly S. Hein</json:string><json:string>Floranne Ernste</json:string><json:string>Review Boards</json:string><json:string>Shreyasee Amin</json:string><json:string>Additional</json:string><json:string>Erik Peterson</json:string><json:string>Reed</json:string><json:string>AL Table</json:string><json:string>AL Figure</json:string><json:string>Cynthia S. Crowson</json:string></persName><placeName><json:string>Minneapolis</json:string><json:string>Rochester</json:string><json:string>Bristol</json:string><json:string>MN</json:string></placeName><ref_url></ref_url><ref_bibl></ref_bibl><bibl></bibl></unitex></namedEntities><ark><json:string>ark:/67375/WNG-XQC5PHV8-N</json:string></ark><categories><wos><json:string>1 - science</json:string><json:string>2 - rheumatology</json:string></wos><scienceMetrix></scienceMetrix><scopus><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Pharmacology (medical)</json:string><json:string>1 - Life Sciences</json:string><json:string>2 - Immunology and Microbiology</json:string><json:string>3 - Immunology</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Rheumatology</json:string><json:string>1 - Health Sciences</json:string><json:string>2 - Medicine</json:string><json:string>3 - Immunology and Allergy</json:string></scopus><inist><json:string>1 - sciences appliquees, technologies et medecines</json:string><json:string>2 - sciences biologiques et medicales</json:string><json:string>3 - sciences medicales</json:string></inist></categories><publicationDate>2012</publicationDate><copyrightDate>2012</copyrightDate><doi><json:string>10.1002/art.34659</json:string></doi><id>AB92DF4B4E124024B3FC801A66D93257186F75A1</id><score>1</score><fulltext><json:item><extension>pdf</extension><original>true</original><mimetype>application/pdf</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-XQC5PHV8-N/fulltext.pdf</uri></json:item><json:item><extension>zip</extension><original>false</original><mimetype>application/zip</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-XQC5PHV8-N/bundle.zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/ark:/67375/WNG-XQC5PHV8-N/fulltext.tei"><teiHeader><fileDesc><titleStmt><title level="a" type="main">Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course</title><title level="a" type="short" xml:lang="en">Biomarkers of Disease Activity in Dermatomyositis</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><licence>Copyright © 2012 by the American College of Rheumatology</licence></availability><date type="published" when="2012-12"></date></publicationStmt><notesStmt><note type="content-type" subtype="article" source="article" scheme="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</note><note type="publication-type" subtype="journal" scheme="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</note></notesStmt><sourceDesc><biblStruct type="article"><analytic><title level="a" type="main">Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course</title><title level="a" type="short" xml:lang="en">Biomarkers of Disease Activity in Dermatomyositis</title><author xml:id="author-0000" role="corresp"><persName><forename type="first">Ann M.</forename><surname>Reed</surname></persName><email>reed.ann18@mayo.edu</email><affiliation><address><addrLine>Mayo Clinic</addrLine><addrLine>Rochester, Minnesota</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><author xml:id="author-0001"><persName><forename type="first">Erik</forename><surname>Peterson</surname></persName><affiliation><orgName type="institution">University of Minnesota</orgName><address><addrLine>Minneapolis</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><author xml:id="author-0002"><persName><forename type="first">Hatice</forename><surname>Bilgic</surname></persName><affiliation><orgName type="institution">University of Minnesota</orgName><address><addrLine>Minneapolis</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><author xml:id="author-0003"><persName><forename type="first">Steven R.</forename><surname>Ytterberg</surname></persName><affiliation><address><addrLine>Mayo Clinic</addrLine><addrLine>Rochester, Minnesota</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><author xml:id="author-0004"><persName><forename type="first">Shreyasee</forename><surname>Amin</surname></persName><affiliation><address><addrLine>Mayo Clinic</addrLine><addrLine>Rochester, Minnesota</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><author xml:id="author-0005"><persName><forename type="first">Molly S.</forename><surname>Hein</surname></persName><affiliation><address><addrLine>Mayo Clinic</addrLine><addrLine>Rochester, Minnesota</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><author xml:id="author-0006"><persName><forename type="first">Cynthia S.</forename><surname>Crowson</surname></persName><affiliation><address><addrLine>Mayo Clinic</addrLine><addrLine>Rochester, Minnesota</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><author xml:id="author-0007"><persName><forename type="first">Floranne</forename><surname>Ernste</surname></persName><affiliation><address><addrLine>Mayo Clinic</addrLine><addrLine>Rochester, Minnesota</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><author xml:id="author-0008"><persName><forename type="first">Emily Baechler</forename><surname>Gillespie</surname></persName><affiliation><orgName type="institution">University of Minnesota</orgName><address><addrLine>Minneapolis</addrLine><country key="US" xml:lang="en">UNITED STATES</country></address></affiliation></author><idno type="istex">AB92DF4B4E124024B3FC801A66D93257186F75A1</idno><idno type="ark">ark:/67375/WNG-XQC5PHV8-N</idno><idno type="DOI">10.1002/art.34659</idno><idno type="unit">ART34659</idno><idno type="toTypesetVersion">file:ART.ART34659.pdf</idno></analytic><monogr><title level="j" type="main">Arthritis & Rheumatism</title><title level="j" type="alt">ARTHRITIS AND RHEUMATISM</title><idno type="pISSN">0004-3591</idno><idno type="eISSN">1529-0131</idno><idno type="book-DOI">10.1002/(ISSN)1529-0131</idno><idno type="book-part-DOI">10.1002/art.v64.12</idno><idno type="product">ART</idno><imprint><biblScope unit="vol">64</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="4078">4078</biblScope><biblScope unit="page" to="4086">4086</biblScope><biblScope unit="page-count">9</biblScope><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2012-12"></date></imprint></monogr></biblStruct></sourceDesc></fileDesc><encodingDesc><schemaRef type="ODD" url="https://xml-schema.delivery.istex.fr/tei-istex.odd"></schemaRef><appInfo><application ident="pub2tei" version="1.0.10" when="2019-12-20"><label>pub2TEI-ISTEX</label><desc>A set of style sheets for converting XML documents encoded in various scientific publisher formats into a common TEI format.
<ref target="http://www.tei-c.org/">We use TEI</ref></desc></application></appInfo></encodingDesc><profileDesc><abstract xml:lang="en" style="main"><head>Abstract</head><head>Objective</head><p>Muscle enzyme levels are insensitive markers of disease activity in juvenile and adult dermatomyositis (DM), especially during the active treatment phase. To improve our ability to monitor DM disease activity longitudinally, especially in the presence of immunomodulating agents, we prospectively evaluated whether interferon (IFN)–dependent peripheral blood gene and chemokine signatures could serve as sensitive and responsive biomarkers for change in disease activity in adult and juvenile DM.</p><head>Methods</head><p>Peripheral blood and clinical data were collected from 51 patients with juvenile or adult DM prospectively over 2 study visits. We performed disease activity measurements and calculated whole‐blood type I IFN gene and chemokine scores. We also measured serum levels of other proinflammatory cytokines, including interleukin‐6 (IL‐6).</p><head>Results</head><p>Changes in juvenile and adult DM global disease activity correlated positively and significantly with changes in the type I IFN gene score before adjustment for medication use (r = 0.33, <hi rend="italic">P</hi> = 0.023) and with changes in the IFN chemokine score before and after adjustment for medication use (r = 0.53, <hi rend="italic">P</hi> < 0.001 and r = 0.50, <hi rend="italic">P</hi> < 0.001, respectively). Changes in muscle and extramuscular visual analog scale (VAS) scores correlated positively with changes in IFN gene and chemokine scores (<hi rend="italic">P</hi> = 0.002, <hi rend="italic">P</hi> < 0.001, <hi rend="italic">P</hi> = 0.095, <hi rend="italic">P</hi> < 0.001). Serum levels of IL‐6, IL‐8, and tumor necrosis factor α (TNFα) correlated positively with changes in global, muscle, and extramuscular VAS scores (<hi rend="italic">P</hi> < 0.05).</p><head>Conclusion</head><p>Our findings suggest that changes in type I IFN gene and chemokine scores as well as in levels of IL‐6, IL‐8, and TNFα may serve as sensitive and responsive longitudinal biomarkers of change in disease activity in juvenile and adult DM, even in the presence of immunomodulating agents.</p></abstract><textClass><keywords rend="articleCategory"><term>Myositis</term></keywords><keywords rend="tocHeading1"><term>Myositis</term></keywords></textClass><langUsage><language ident="en"></language></langUsage></profileDesc><revisionDesc><change when="2019-12-20" who="#istex" xml:id="pub2tei">formatting</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><extension>txt</extension><original>false</original><mimetype>text/plain</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-XQC5PHV8-N/fulltext.txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1529-0131</doi><issn type="print">0004-3591</issn><issn type="electronic">1529-0131</issn><idGroup><id type="product" value="ART"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="ARTHRITIS AND RHEUMATISM">Arthritis & Rheumatism</title><title type="short">Arthritis & Rheumatism</title></titleGroup></publicationMeta><publicationMeta level="part" position="120"><doi origin="wiley" registered="yes">10.1002/art.v64.12</doi><numberingGroup><numbering type="journalVolume" number="64">64</numbering><numbering type="journalIssue">12</numbering></numberingGroup><coverDate startDate="2012-12">December 2012</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="320" status="forIssue"><doi origin="wiley" registered="yes">10.1002/art.34659</doi><idGroup><id type="unit" value="ART34659"></id></idGroup><countGroup><count type="pageTotal" number="9"></count></countGroup><titleGroup><title type="articleCategory">Myositis</title><title type="tocHeading1">Myositis</title></titleGroup><copyright ownership="thirdParty">Copyright © 2012 by the American College of Rheumatology</copyright><eventGroup><event type="manuscriptReceived" date="2012-01-15"></event><event type="manuscriptAccepted" date="2012-07-26"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:3.2.3 mode:FullText" date="2013-08-05"></event><event type="publishedOnlineAccepted" date="2012-08-08"></event><event type="publishedOnlineFinalForm" date="2012-11-28"></event><event type="firstOnline" date="2012-11-28"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-01-05"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.3.7 mode:FullText" date="2015-03-24"></event></eventGroup><numberingGroup><numbering type="pageFirst">4078</numbering><numbering type="pageLast">4086</numbering></numberingGroup><correspondenceTo>Mayo Clinic, Division of Rheumatology, E15, 200 First Street SW, Rochester, MN 55905</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:ART.ART34659.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="2"></count><count type="tableTotal" number="4"></count><count type="referenceTotal" number="26"></count><count type="wordTotal" number="6740"></count></countGroup><titleGroup><title type="main" xml:lang="en">Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course</title><title type="short" xml:lang="en">Biomarkers of Disease Activity in Dermatomyositis</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Ann M.</givenNames><familyName>Reed</familyName></personName><contactDetails><email>reed.ann18@mayo.edu</email></contactDetails></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af2" noteRef="#fn1"><personName><givenNames>Erik</givenNames><familyName>Peterson</familyName></personName></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Hatice</givenNames><familyName>Bilgic</familyName></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Steven R.</givenNames><familyName>Ytterberg</familyName></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Shreyasee</givenNames><familyName>Amin</familyName></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Molly S.</givenNames><familyName>Hein</familyName></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Cynthia S.</givenNames><familyName>Crowson</familyName></personName></creator><creator xml:id="au8" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Floranne</givenNames><familyName>Ernste</familyName></personName></creator><creator xml:id="au9" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Emily Baechler</givenNames><familyName>Gillespie</familyName></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="US" type="organization"><unparsedAffiliation>Mayo Clinic, Rochester, Minnesota</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="US" type="organization"><unparsedAffiliation>University of Minnesota, Minneapolis</unparsedAffiliation></affiliation></affiliationGroup><fundingInfo><fundingAgency>Minnesota Partnership for Biotechnology and Medical Genomics</fundingAgency></fundingInfo><fundingInfo><fundingAgency>National Institute of Arthritis and Musculoskeletal and Skin Diseases</fundingAgency></fundingInfo><fundingInfo><fundingAgency>NIH</fundingAgency></fundingInfo><fundingInfo><fundingAgency>Arthritis Foundation</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><section xml:id="abs1-1"><title type="main">Objective</title><p>Muscle enzyme levels are insensitive markers of disease activity in juvenile and adult dermatomyositis (DM), especially during the active treatment phase. To improve our ability to monitor DM disease activity longitudinally, especially in the presence of immunomodulating agents, we prospectively evaluated whether interferon (IFN)–dependent peripheral blood gene and chemokine signatures could serve as sensitive and responsive biomarkers for change in disease activity in adult and juvenile DM.</p></section><section xml:id="abs1-2"><title type="main">Methods</title><p>Peripheral blood and clinical data were collected from 51 patients with juvenile or adult DM prospectively over 2 study visits. We performed disease activity measurements and calculated whole‐blood type I IFN gene and chemokine scores. We also measured serum levels of other proinflammatory cytokines, including interleukin‐6 (IL‐6).</p></section><section xml:id="abs1-3"><title type="main">Results</title><p>Changes in juvenile and adult DM global disease activity correlated positively and significantly with changes in the type I IFN gene score before adjustment for medication use (r = 0.33, <i>P</i> = 0.023) and with changes in the IFN chemokine score before and after adjustment for medication use (r = 0.53, <i>P</i> < 0.001 and r = 0.50, <i>P</i> < 0.001, respectively). Changes in muscle and extramuscular visual analog scale (VAS) scores correlated positively with changes in IFN gene and chemokine scores (<i>P</i> = 0.002, <i>P</i> < 0.001, <i>P</i> = 0.095, <i>P</i> < 0.001). Serum levels of IL‐6, IL‐8, and tumor necrosis factor α (TNFα) correlated positively with changes in global, muscle, and extramuscular VAS scores (<i>P</i> < 0.05).</p></section><section xml:id="abs1-4"><title type="main">Conclusion</title><p>Our findings suggest that changes in type I IFN gene and chemokine scores as well as in levels of IL‐6, IL‐8, and TNFα may serve as sensitive and responsive longitudinal biomarkers of change in disease activity in juvenile and adult DM, even in the presence of immunomodulating agents.</p></section></abstract></abstractGroup></contentMeta><noteGroup><note xml:id="fn1"><p>Dr. Peterson has received consulting fees, speaking fees, and/or honoraria from Bristol‐Myers Squibb (less than $10,000).</p></note></noteGroup></header></component></istex:document></istex:metadataXml><mods version="3.6"><titleInfo lang="en"><title>Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Biomarkers of Disease Activity in Dermatomyositis</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course</title></titleInfo><name type="personal"><namePart type="given">Ann M.</namePart><namePart type="family">Reed</namePart><affiliation>Mayo Clinic, Rochester, Minnesota</affiliation><affiliation>E-mail: reed.ann18@mayo.edu</affiliation><affiliation>Correspondence address: Mayo Clinic, Division of Rheumatology, E15, 200 First Street SW, Rochester, MN 55905</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Erik</namePart><namePart type="family">Peterson</namePart><affiliation>University of Minnesota, Minneapolis</affiliation><description>Dr. Peterson has received consulting fees, speaking fees, and/or honoraria from Bristol‐Myers Squibb (less than $10,000).</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Hatice</namePart><namePart type="family">Bilgic</namePart><affiliation>University of Minnesota, Minneapolis</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Steven R.</namePart><namePart type="family">Ytterberg</namePart><affiliation>Mayo Clinic, Rochester, Minnesota</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Shreyasee</namePart><namePart type="family">Amin</namePart><affiliation>Mayo Clinic, Rochester, Minnesota</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Molly S.</namePart><namePart type="family">Hein</namePart><affiliation>Mayo Clinic, Rochester, Minnesota</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Cynthia S.</namePart><namePart type="family">Crowson</namePart><affiliation>Mayo Clinic, Rochester, Minnesota</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Floranne</namePart><namePart type="family">Ernste</namePart><affiliation>Mayo Clinic, Rochester, Minnesota</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Emily Baechler</namePart><namePart type="family">Gillespie</namePart><affiliation>University of Minnesota, Minneapolis</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre type="article" displayLabel="article" authority="ISTEX" authorityURI="https://content-type.data.istex.fr" valueURI="https://content-type.data.istex.fr/ark:/67375/XTP-6N5SZHKN-D">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2012-12</dateIssued><dateCaptured encoding="w3cdtf">2012-01-15</dateCaptured><dateValid encoding="w3cdtf">2012-07-26</dateValid><copyrightDate encoding="w3cdtf">2012</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><extent unit="figures">2</extent><extent unit="tables">4</extent><extent unit="references">26</extent><extent unit="words">6740</extent></physicalDescription><abstract lang="en">Objective: Muscle enzyme levels are insensitive markers of disease activity in juvenile and adult dermatomyositis (DM), especially during the active treatment phase. To improve our ability to monitor DM disease activity longitudinally, especially in the presence of immunomodulating agents, we prospectively evaluated whether interferon (IFN)–dependent peripheral blood gene and chemokine signatures could serve as sensitive and responsive biomarkers for change in disease activity in adult and juvenile DM. Methods: Peripheral blood and clinical data were collected from 51 patients with juvenile or adult DM prospectively over 2 study visits. We performed disease activity measurements and calculated whole‐blood type I IFN gene and chemokine scores. We also measured serum levels of other proinflammatory cytokines, including interleukin‐6 (IL‐6). Results: Changes in juvenile and adult DM global disease activity correlated positively and significantly with changes in the type I IFN gene score before adjustment for medication use (r = 0.33, P = 0.023) and with changes in the IFN chemokine score before and after adjustment for medication use (r = 0.53, P < 0.001 and r = 0.50, P < 0.001, respectively). Changes in muscle and extramuscular visual analog scale (VAS) scores correlated positively with changes in IFN gene and chemokine scores (P = 0.002, P < 0.001, P = 0.095, P < 0.001). Serum levels of IL‐6, IL‐8, and tumor necrosis factor α (TNFα) correlated positively with changes in global, muscle, and extramuscular VAS scores (P < 0.05). Conclusion: Our findings suggest that changes in type I IFN gene and chemokine scores as well as in levels of IL‐6, IL‐8, and TNFα may serve as sensitive and responsive longitudinal biomarkers of change in disease activity in juvenile and adult DM, even in the presence of immunomodulating agents.</abstract><note type="funding">Minnesota Partnership for Biotechnology and Medical Genomics</note><note type="funding">National Institute of Arthritis and Musculoskeletal and Skin Diseases</note><note type="funding">NIH</note><note type="funding">Arthritis Foundation</note><relatedItem type="host"><titleInfo><title>Arthritis & Rheumatism</title></titleInfo><titleInfo type="abbreviated"><title>Arthritis & Rheumatism</title></titleInfo><genre type="journal" authority="ISTEX" authorityURI="https://publication-type.data.istex.fr" valueURI="https://publication-type.data.istex.fr/ark:/67375/JMC-0GLKJH51-B">journal</genre><subject><genre>article-category</genre><topic>Myositis</topic><topic>Myositis</topic></subject><identifier type="ISSN">0004-3591</identifier><identifier type="eISSN">1529-0131</identifier><identifier type="DOI">10.1002/(ISSN)1529-0131</identifier><identifier type="PublisherID">ART</identifier><part><date>2012</date><detail type="volume"><caption>vol.</caption><number>64</number></detail><detail type="issue"><caption>no.</caption><number>12</number></detail><extent unit="pages"><start>4078</start><end>4086</end><total>9</total></extent></part></relatedItem><relatedItem type="references" displayLabel="cit1"><titleInfo><title>Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies</title></titleInfo><name type="personal"><namePart type="given">FW</namePart><namePart type="family">Miller</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LG</namePart><namePart type="family">Rider</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">YL</namePart><namePart type="family">Chung</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Cooper</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Danko</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">V</namePart><namePart type="family">Farewell</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Miller FW, Rider LG, Chung YL, Cooper R, Danko K, Farewell V, et al. Proposed preliminary core set measures for disease outcome assessment in adult and juvenile idiopathic inflammatory myopathies. Rheumatology (Oxford) 2001; 40: 1262–73.</note><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>40</number></detail><extent unit="pages"><start>1262</start><end>73</end></extent></part><relatedItem type="host"><titleInfo><title>Rheumatology (Oxford)</title></titleInfo><part><date>2001</date><detail type="volume"><caption>vol.</caption><number>40</number></detail><extent unit="pages"><start>1262</start><end>73</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit2"><titleInfo><title>Classification and treatment of the juvenile idiopathic inflammatory myopathies</title></titleInfo><name type="personal"><namePart type="given">LG</namePart><namePart type="family">Rider</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">FW</namePart><namePart type="family">Miller</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rider LG, Miller FW. Classification and treatment of the juvenile idiopathic inflammatory myopathies. Rheum Dis Clin North Am 1997; 23: 619–55.</note><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>619</start><end>55</end></extent></part><relatedItem type="host"><titleInfo><title>Rheum Dis Clin North Am</title></titleInfo><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>23</number></detail><extent unit="pages"><start>619</start><end>55</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit3"><titleInfo><title>An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity</title></titleInfo><name type="personal"><namePart type="given">EC</namePart><namePart type="family">Baechler</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JW</namePart><namePart type="family">Bauer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CA</namePart><namePart type="family">Slattery</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WA</namePart><namePart type="family">Ortmann</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KJ</namePart><namePart type="family">Espe</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Novitzke</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Baechler EC, Bauer JW, Slattery CA, Ortmann WA, Espe KJ, Novitzke J, et al. An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 2007; 13: 59–68.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>59</start><end>68</end></extent></part><relatedItem type="host"><titleInfo><title>Mol Med</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>13</number></detail><extent unit="pages"><start>59</start><end>68</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit4"><titleInfo><title>cDNA microarrays reveal distinct gene expression clusters in idiopathic inflammatory myopathies</title></titleInfo><name type="personal"><namePart type="given">X</namePart><namePart type="family">Zhou</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MM</namePart><namePart type="family">Dimachkie</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Xiong</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">FK</namePart><namePart type="family">Tan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">FC</namePart><namePart type="family">Arnett</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Zhou X, Dimachkie MM, Xiong M, Tan FK, Arnett FC. cDNA microarrays reveal distinct gene expression clusters in idiopathic inflammatory myopathies. Med Sci Monit 2004; 10: BR191–7.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>BR191</start><end>7</end></extent></part><relatedItem type="host"><titleInfo><title>Med Sci Monit</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>10</number></detail><extent unit="pages"><start>BR191</start><end>7</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit5"><titleInfo><title>Interleukin‐6 and type I interferon–regulated genes and chemokines mark disease activity in dermatomyositis</title></titleInfo><name type="personal"><namePart type="given">H</namePart><namePart type="family">Bilgic</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SR</namePart><namePart type="family">Ytterberg</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Amin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KT</namePart><namePart type="family">McNallan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JC</namePart><namePart type="family">Wilson</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Koeuth</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bilgic H, Ytterberg SR, Amin S, McNallan KT, Wilson JC, Koeuth T, et al. Interleukin‐6 and type I interferon–regulated genes and chemokines mark disease activity in dermatomyositis. Arthritis Rheum 2009; 60: 3436–46.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>3436</start><end>46</end></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>3436</start><end>46</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit6"><titleInfo><title>Polymyositis and dermatomyositis (second of two parts)</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Bohan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JB</namePart><namePart type="family">Peter</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med 1975; 292: 403–7.</note><part><date>1975</date><detail type="volume"><caption>vol.</caption><number>292</number></detail><extent unit="pages"><start>403</start><end>7</end></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>1975</date><detail type="volume"><caption>vol.</caption><number>292</number></detail><extent unit="pages"><start>403</start><end>7</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit7"><titleInfo><title>Polymyositis and dermatomyositis (first of two parts)</title></titleInfo><name type="personal"><namePart type="given">A</namePart><namePart type="family">Bohan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JB</namePart><namePart type="family">Peter</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975; 292: 344–7.</note><part><date>1975</date><detail type="volume"><caption>vol.</caption><number>292</number></detail><extent unit="pages"><start>344</start><end>7</end></extent></part><relatedItem type="host"><titleInfo><title>N Engl J Med</title></titleInfo><part><date>1975</date><detail type="volume"><caption>vol.</caption><number>292</number></detail><extent unit="pages"><start>344</start><end>7</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit8"><titleInfo><title>International consensus outcome measures for patients with idiopathic inflammatory myopathies: development and initial validation of myositis activity and damage indices in patients with adult onset disease</title></titleInfo><name type="personal"><namePart type="given">DA</namePart><namePart type="family">Isenberg</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">E</namePart><namePart type="family">Allen</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">V</namePart><namePart type="family">Farewell</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MR</namePart><namePart type="family">Ehrenstein</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MG</namePart><namePart type="family">Hanna</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">IE</namePart><namePart type="family">Lundberg</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="corporate"><namePart>International Myositis and Clinical Studies Group (IMACS)</namePart></name><genre>journal-article</genre><note type="citation/reference">Isenberg DA, Allen E, Farewell V, Ehrenstein MR, Hanna MG, Lundberg IE, et al, for the International Myositis and Clinical Studies Group (IMACS). International consensus outcome measures for patients with idiopathic inflammatory myopathies: development and initial validation of myositis activity and damage indices in patients with adult onset disease. Rheumatology (Oxford) 2004; 43: 49–54.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>43</number></detail><extent unit="pages"><start>49</start><end>54</end></extent></part><relatedItem type="host"><titleInfo><title>Rheumatology (Oxford)</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>43</number></detail><extent unit="pages"><start>49</start><end>54</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit9"><titleInfo><title>International consensus on preliminary definitions of improvement in adult and juvenile myositis</title></titleInfo><name type="personal"><namePart type="given">LG</namePart><namePart type="family">Rider</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EH</namePart><namePart type="family">Giannini</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">HI</namePart><namePart type="family">Brunner</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Ruperto</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">James‐Newton</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AM</namePart><namePart type="family">Reed</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="corporate"><namePart>International Myositis Assessment and Clinical Studies Group</namePart></name><genre>journal-article</genre><note type="citation/reference">Rider LG, Giannini EH, Brunner HI, Ruperto N, James‐Newton L, Reed AM, et al, for the International Myositis Assessment and Clinical Studies Group. International consensus on preliminary definitions of improvement in adult and juvenile myositis. Arthritis Rheum 2004; 50: 2281–90.</note><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>2281</start><end>90</end></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>50</number></detail><extent unit="pages"><start>2281</start><end>90</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit10"><titleInfo><title>Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies</title></titleInfo><name type="personal"><namePart type="given">LG</namePart><namePart type="family">Rider</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Koziol</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EH</namePart><namePart type="family">Giannini</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MS</namePart><namePart type="family">Jain</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MR</namePart><namePart type="family">Smith</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">K</namePart><namePart type="family">Whitney‐Mahoney</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rider LG, Koziol D, Giannini EH, Jain MS, Smith MR, Whitney‐Mahoney K, et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken) 2010; 62: 465–72.</note><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><extent unit="pages"><start>465</start><end>72</end></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Care Res (Hoboken)</title></titleInfo><part><date>2010</date><detail type="volume"><caption>vol.</caption><number>62</number></detail><extent unit="pages"><start>465</start><end>72</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit11"><titleInfo><title>Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function</title></titleInfo><name type="personal"><namePart type="given">DJ</namePart><namePart type="family">Lovell</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">CB</namePart><namePart type="family">Lindsley</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RM</namePart><namePart type="family">Rennebohm</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SH</namePart><namePart type="family">Ballinger</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SL</namePart><namePart type="family">Bowyer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">EH</namePart><namePart type="family">Giannini</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="corporate"><namePart>Juvenile Dermatomyositis Disease Activity Collaborative Study Group</namePart></name><genre>journal-article</genre><note type="citation/reference">Lovell DJ, Lindsley CB, Rennebohm RM, Ballinger SH, Bowyer SL, Giannini EH, et al, in cooperation with the Juvenile Dermatomyositis Disease Activity Collaborative Study Group. Development of validated disease activity and damage indices for the juvenile idiopathic inflammatory myopathies. II. The Childhood Myositis Assessment Scale (CMAS): a quantitative tool for the evaluation of muscle function. Arthritis Rheum 1999; 42: 2213–9.</note><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>2213</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>1999</date><detail type="volume"><caption>vol.</caption><number>42</number></detail><extent unit="pages"><start>2213</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit12"><titleInfo><title>Interferon‐inducible gene expression signature in peripheral blood cells of patients with severe lupus</title></titleInfo><name type="personal"><namePart type="given">EC</namePart><namePart type="family">Baechler</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">FM</namePart><namePart type="family">Batliwalla</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Karypis</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PM</namePart><namePart type="family">Gaffney</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">WA</namePart><namePart type="family">Ortmann</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KJ</namePart><namePart type="family">Espe</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, et al. Interferon‐inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 2003; 100: 2610–5.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>2610</start><end>5</end></extent></part><relatedItem type="host"><titleInfo><title>Proc Natl Acad Sci U S A</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>100</number></detail><extent unit="pages"><start>2610</start><end>5</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit13"><titleInfo><title>von Willebrand factor in juvenile dermatomyositis</title></titleInfo><name type="personal"><namePart type="given">BJ</namePart><namePart type="family">Bloom</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LB</namePart><namePart type="family">Tucker</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LC</namePart><namePart type="family">Miller</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JG</namePart><namePart type="family">Schaller</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Bloom BJ, Tucker LB, Miller LC, Schaller JG. von Willebrand factor in juvenile dermatomyositis. J Rheumatol 1995; 22: 320–5.</note><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>320</start><end>5</end></extent></part><relatedItem type="host"><titleInfo><title>J Rheumatol</title></titleInfo><part><date>1995</date><detail type="volume"><caption>vol.</caption><number>22</number></detail><extent unit="pages"><start>320</start><end>5</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit14"><titleInfo><title>Early preplasma cells define a tolerance checkpoint for autoreactive B cells</title></titleInfo><name type="personal"><namePart type="given">DA</namePart><namePart type="family">Culton</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">BP</namePart><namePart type="family">O'Conner</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KL</namePart><namePart type="family">Conway</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Diz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Rutan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">BJ</namePart><namePart type="family">Vilen</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Culton DA, O'Conner BP, Conway KL, Diz R, Rutan J, Vilen BJ, et al. Early preplasma cells define a tolerance checkpoint for autoreactive B cells. J Immunol 2006; 176: 790–802.</note><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>176</number></detail><extent unit="pages"><start>790</start><end>802</end></extent></part><relatedItem type="host"><titleInfo><title>J Immunol</title></titleInfo><part><date>2006</date><detail type="volume"><caption>vol.</caption><number>176</number></detail><extent unit="pages"><start>790</start><end>802</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit15"><titleInfo><title>The predominance of β (CC) chemokine transcripts in idiopathic inflammatory muscle diseases</title></titleInfo><name type="personal"><namePart type="given">EM</namePart><namePart type="family">Adams</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Kirkley</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Eidelman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">J</namePart><namePart type="family">Dohlman</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PH</namePart><namePart type="family">Plotz</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Adams EM, Kirkley J, Eidelman G, Dohlman J, Plotz PH. The predominance of β (CC) chemokine transcripts in idiopathic inflammatory muscle diseases. Proc Assoc Am Physicians 1997; 109: 275–85.</note><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>109</number></detail><extent unit="pages"><start>275</start><end>85</end></extent></part><relatedItem type="host"><titleInfo><title>Proc Assoc Am Physicians</title></titleInfo><part><date>1997</date><detail type="volume"><caption>vol.</caption><number>109</number></detail><extent unit="pages"><start>275</start><end>85</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit16"><titleInfo><title>Expression of the β chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory myopathies</title></titleInfo><name type="personal"><namePart type="given">M</namePart><namePart type="family">Civatte</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Bartoli</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Schleinitz</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Chetaille</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JF</namePart><namePart type="family">Pellissier</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">D</namePart><namePart type="family">Figarella‐Branger</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Civatte M, Bartoli C, Schleinitz N, Chetaille B, Pellissier JF, Figarella‐Branger D. Expression of the β chemokines CCL3, CCL4, CCL5 and their receptors in idiopathic inflammatory myopathies. Neuropathol Appl Neurobiol 2005; 31: 70–9.</note><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>70</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>Neuropathol Appl Neurobiol</title></titleInfo><part><date>2005</date><detail type="volume"><caption>vol.</caption><number>31</number></detail><extent unit="pages"><start>70</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit17"><titleInfo><title>Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies</title></titleInfo><name type="personal"><namePart type="given">LG</namePart><namePart type="family">Rider</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AS</namePart><namePart type="family">Schiffenbauer</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Zito</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KL</namePart><namePart type="family">Lim</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Ahmed</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LS</namePart><namePart type="family">Zemel</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Rider LG, Schiffenbauer AS, Zito M, Lim KL, Ahmed A, Zemel LS, et al. Neopterin and quinolinic acid are surrogate measures of disease activity in the juvenile idiopathic inflammatory myopathies. Clin Chem 2002; 48: 1681–8.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>48</number></detail><extent unit="pages"><start>1681</start><end>8</end></extent></part><relatedItem type="host"><titleInfo><title>Clin Chem</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>48</number></detail><extent unit="pages"><start>1681</start><end>8</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit18"><titleInfo><title>Correlation of serum neopterin concentrations with disease activity in juvenile dermatomyositis</title></titleInfo><name type="personal"><namePart type="given">F</namePart><namePart type="family">De Benedetti</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">De Amici</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">L</namePart><namePart type="family">Aramini</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Ruperto</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Martini</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">De Benedetti F, De Amici M, Aramini L, Ruperto N, Martini A. Correlation of serum neopterin concentrations with disease activity in juvenile dermatomyositis. Arch Dis Child 1993; 69: 232–5.</note><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>69</number></detail><extent unit="pages"><start>232</start><end>5</end></extent></part><relatedItem type="host"><titleInfo><title>Arch Dis Child</title></titleInfo><part><date>1993</date><detail type="volume"><caption>vol.</caption><number>69</number></detail><extent unit="pages"><start>232</start><end>5</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit19"><titleInfo><title>Flow cytometric analysis of lymphocyte subpopulations and Th1/Th2 balance in patients with polymyositis and dermatomyositis</title></titleInfo><name type="personal"><namePart type="given">W</namePart><namePart type="family">Ishii</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Matsuda</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Shimojima</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Itoh</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">T</namePart><namePart type="family">Sumida</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Ikeda</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Ishii W, Matsuda M, Shimojima Y, Itoh S, Sumida T, Ikeda S. Flow cytometric analysis of lymphocyte subpopulations and Th1/Th2 balance in patients with polymyositis and dermatomyositis. Intern Med 2008; 47: 1593–9.</note><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>1593</start><end>9</end></extent></part><relatedItem type="host"><titleInfo><title>Intern Med</title></titleInfo><part><date>2008</date><detail type="volume"><caption>vol.</caption><number>47</number></detail><extent unit="pages"><start>1593</start><end>9</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit20"><titleInfo><title>Differential expression of chemokines in inflammatory myopathies</title></titleInfo><name type="personal"><namePart type="given">JL</namePart><namePart type="family">De Bleecker</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">De Paepe</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">IE</namePart><namePart type="family">Vanwalleghem</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JM</namePart><namePart type="family">Schroder</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">De Bleecker JL, De Paepe B, Vanwalleghem IE, Schroder JM. Differential expression of chemokines in inflammatory myopathies. Neurology 2002; 58: 1779–85.</note><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>58</number></detail><extent unit="pages"><start>1779</start><end>85</end></extent></part><relatedItem type="host"><titleInfo><title>Neurology</title></titleInfo><part><date>2002</date><detail type="volume"><caption>vol.</caption><number>58</number></detail><extent unit="pages"><start>1779</start><end>85</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit21"><titleInfo><title>Elevated serum interferon‐α activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty‐six months of therapy</title></titleInfo><name type="personal"><namePart type="given">TB</namePart><namePart type="family">Niewold</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SN</namePart><namePart type="family">Kariuki</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">GA</namePart><namePart type="family">Morgan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">S</namePart><namePart type="family">Shrestha</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">LM</namePart><namePart type="family">Pachman</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Niewold TB, Kariuki SN, Morgan GA, Shrestha S, Pachman LM. Elevated serum interferon‐α activity in juvenile dermatomyositis: associations with disease activity at diagnosis and after thirty‐six months of therapy. Arthritis Rheum 2009; 60: 1815–24.</note><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>1815</start><end>24</end></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2009</date><detail type="volume"><caption>vol.</caption><number>60</number></detail><extent unit="pages"><start>1815</start><end>24</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit22"><titleInfo><title>Serum levels of interferon α do not correlate with disease activity in patients with dermatomyositis/polymyositis</title></titleInfo><name type="personal"><namePart type="given">P</namePart><namePart type="family">Krol</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">O</namePart><namePart type="family">Krystufkova</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Polanska</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">H</namePart><namePart type="family">Mann</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Klein</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">O</namePart><namePart type="family">Beran</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Krol P, Krystufkova O, Polanska M, Mann H, Klein M, Beran O, et al. Serum levels of interferon α do not correlate with disease activity in patients with dermatomyositis/polymyositis. Ann Rheum Dis 2011; 70: 879–80.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>70</number></detail><extent unit="pages"><start>879</start><end>80</end></extent></part><relatedItem type="host"><titleInfo><title>Ann Rheum Dis</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>70</number></detail><extent unit="pages"><start>879</start><end>80</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit23"><titleInfo><title>Interferon β is associated with type 1 interferon‐inducible gene expression in dermatomyositis</title></titleInfo><name type="personal"><namePart type="given">AP</namePart><namePart type="family">Liao</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">M</namePart><namePart type="family">Salajegheh</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Nazareno</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JC</namePart><namePart type="family">Kagan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">RG</namePart><namePart type="family">Jubin</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SA</namePart><namePart type="family">Greenberg</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Liao AP, Salajegheh M, Nazareno R, Kagan JC, Jubin RG, Greenberg SA. Interferon β is associated with type 1 interferon‐inducible gene expression in dermatomyositis. Ann Rheum Dis 2011; 70: 831–6.</note><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>70</number></detail><extent unit="pages"><start>831</start><end>6</end></extent></part><relatedItem type="host"><titleInfo><title>Ann Rheum Dis</title></titleInfo><part><date>2011</date><detail type="volume"><caption>vol.</caption><number>70</number></detail><extent unit="pages"><start>831</start><end>6</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit24"><titleInfo><title>Interleukin‐17 increases the effects of IL‐1β on muscle cells: arguments for the role of T cells in the pathogenesis of myositis</title></titleInfo><name type="personal"><namePart type="given">G</namePart><namePart type="family">Chevrel</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">G</namePart><namePart type="family">Page</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">C</namePart><namePart type="family">Granet</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">N</namePart><namePart type="family">Streichenberger</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">A</namePart><namePart type="family">Varennes</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">P</namePart><namePart type="family">Miossec</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Chevrel G, Page G, Granet C, Streichenberger N, Varennes A, Miossec P. Interleukin‐17 increases the effects of IL‐1β on muscle cells: arguments for the role of T cells in the pathogenesis of myositis. J Neuroimmunol 2003; 137: 125–33.</note><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>137</number></detail><extent unit="pages"><start>125</start><end>33</end></extent></part><relatedItem type="host"><titleInfo><title>J Neuroimmunol</title></titleInfo><part><date>2003</date><detail type="volume"><caption>vol.</caption><number>137</number></detail><extent unit="pages"><start>125</start><end>33</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit25"><titleInfo><title>Type I interferon–inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis</title></titleInfo><name type="personal"><namePart type="given">RJ</namePart><namePart type="family">Walsh</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SW</namePart><namePart type="family">Kong</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Y</namePart><namePart type="family">Yao</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">B</namePart><namePart type="family">Jallal</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">PA</namePart><namePart type="family">Kiener</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">JL</namePart><namePart type="family">Pinkus</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Walsh RJ, Kong SW, Yao Y, Jallal B, Kiener PA, Pinkus JL, et al. Type I interferon–inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007; 56: 3784–92.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>3784</start><end>92</end></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>3784</start><end>92</end></extent></part></relatedItem></relatedItem><relatedItem type="references" displayLabel="cit26"><titleInfo><title>Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis</title></titleInfo><name type="personal"><namePart type="given">CM</namePart><namePart type="family">Lopez de Padilla</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AN</namePart><namePart type="family">Vallejo</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">KT</namePart><namePart type="family">McNallan</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">R</namePart><namePart type="family">Vehe</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">SA</namePart><namePart type="family">Smith</namePart><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">AB</namePart><namePart type="family">Dietz</namePart><role><roleTerm type="text">author</roleTerm></role></name><genre>journal-article</genre><note type="citation/reference">Lopez de Padilla CM, Vallejo AN, McNallan KT, Vehe R, Smith SA, Dietz AB, et al. Plasmacytoid dendritic cells in inflamed muscle of patients with juvenile dermatomyositis. Arthritis Rheum 2007; 56: 1658–68.</note><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>1658</start><end>68</end></extent></part><relatedItem type="host"><titleInfo><title>Arthritis Rheum</title></titleInfo><part><date>2007</date><detail type="volume"><caption>vol.</caption><number>56</number></detail><extent unit="pages"><start>1658</start><end>68</end></extent></part></relatedItem></relatedItem><identifier type="istex">AB92DF4B4E124024B3FC801A66D93257186F75A1</identifier><identifier type="ark">ark:/67375/WNG-XQC5PHV8-N</identifier><identifier type="DOI">10.1002/art.34659</identifier><identifier type="ArticleID">ART34659</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2012 by the American College of Rheumatology</accessCondition><recordInfo><recordContentSource authority="ISTEX" authorityURI="https://loaded-corpus.data.istex.fr" valueURI="https://loaded-corpus.data.istex.fr/ark:/67375/XBH-L0C46X92-X">wiley</recordContentSource><recordOrigin>Converted from (version ) to MODS version 3.6.</recordOrigin><recordCreationDate encoding="w3cdtf">2019-11-13</recordCreationDate></recordInfo></mods><json:item><extension>json</extension><original>false</original><mimetype>application/json</mimetype><uri>https://api.istex.fr/ark:/67375/WNG-XQC5PHV8-N/record.json</uri></json:item></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/ChloroquineV1/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002741 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 002741 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= ChloroquineV1
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:AB92DF4B4E124024B3FC801A66D93257186F75A1
|texte= Changes in novel biomarkers of disease activity in juvenile and adult dermatomyositis are sensitive biomarkers of disease course
}}
| This area was generated with Dilib version V0.6.33. |  |